Replies to post #169680 on Biotech Values

[bladerunner1717]

re: GERN

All good points, JohnWayne. (John Wayne was one of my favorite actors. The Searchers and The Man Who Shot Liberty Valence are two masterpieces--both from John Ford--IMO.)

Dr. List's comments have me re-thinking my position here.

Couple of questions, though, for the nay-sayers: Why is no one talking about the response rate of 44%. And, more importantly, in my view, why is no one talking about the two patients who moved from transfusion-dependent to transfusion-independent?


Bladerunner

[biopearl]

John your post makes excellent sense and helps to understand the wording of the abstract. When one looks at the definition of CR by the working group if, for the purposes of the abstract, BM and peripheral criteria are met for the "CR" group what's left?:

"Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH" by the definition of "true"CR

After only a few months of therapy for some of these patients it seems reasonable to expect these would lag (and some patients did not have constitutional symptoms to begin with). If the bone marrow is made whole, evidence for EMH might certainly lag and surely splenic size and liver enlargement would take some time to resolve. With JAK 2 inhibitors its almost as if the sequence were reversed, improved sx, resolution of splenomegaly etc but no bone marrow effect. First comes love then comes marriage...I'll go with the bone marrow. It doesn't seem too far a leap to get to a "true" CR from here this early in the game. Please let me know what you think. Regards, bp